What “Research Use Only” Actually Means Under UK Law

On a great many websites, “research use only” is a line of small print at the bottom of a page that is quite obviously selling something intended for a person. Under UK law it is not a disclaimer at all. It is a description of what the product is — and it stops being accurate the moment the seller says otherwise.

Two separate tests for what counts as a medicine

The Human Medicines Regulations 2012 define a medicinal product through two independent tests. A product only has to meet one.

The first is function. A substance that is administered to a person with a view to restoring, correcting or modifying a physiological function through pharmacological, immunological or metabolic action is a medicinal product by function. This test is about what the substance does.

The second is presentation. Anything presented as having properties for treating or preventing disease is a medicinal product by presentation — and this test does not depend on whether it works, or on what it is. It depends entirely on how it is described.

Presentation is the test that catches suppliers out, because it is created with words rather than chemistry. Two websites can sell physically identical vials from the same batch, and one of them is selling a laboratory reagent while the other is placing an unlicensed medicine on the market. Nothing about the contents differs. The difference is what was written on the page.

What creates presentation in practice

The regulator reads a whole page, in context, as an ordinary reader would. The things that establish presentation are mostly obvious once listed:

Naming a condition, symptom or disease that the compound is said to help. Giving dosing figures in units aimed at a person rather than a laboratory preparation. Publishing protocols, cycles or schedules for human use. Before-and-after imagery, testimonials or reviews describing personal outcomes. Administration instructions written for a person rather than for bench work. Supplying the material in a format that is ready to administer rather than ready to prepare. And editorial content — blog posts, guides, FAQs — that connects a product to a human outcome anywhere on the same site.

MHRA’s own guidance is explicit that this is not limited to formal claims. It lists websites, helplines, testimonials and social media; product names that reference a medical condition; labelling, packaging and graphics; promotional literature across any medium; the physical form the product takes; and the context in which all of it appears. Implicit claims count, and a product name can be one.

Context is doing real work there. A carefully hedged article about the published literature reads very differently when it sits on a page with a price and an add-to-basket button beside it. The commercial surround is part of what makes a statement promotional, which is why “we were only discussing the research” is a weaker defence than it feels like while writing it.

Why the classification matters

Once a product is a medicinal product, it needs a marketing authorisation. Obtaining one means submitting a full dossier covering quality, safety and efficacy — years of work and a great deal of money, which is precisely why none of these compounds has one.

Without that authorisation, two separate prohibitions apply. Regulation 46 prohibits selling or supplying — or offering to sell or supply — an unauthorised medicinal product. Advertising one is a distinct criminal offence under regulation 279, which bars publishing an advertisement for any medicinal product without a marketing authorisation in force. Separately, prescription-only medicines may not be advertised to the general public at all. Enforcement sits with the MHRA.

In practice, regulatory action is rarely the first consequence. Payment processors and hosting providers run their own compliance screening and act considerably faster than any regulator does. For most non-compliant suppliers, the first sign of trouble is a terminated merchant account rather than a letter from the MHRA.

What a compliant supplier looks like

The compliant position is narrower than it first appears, but it is coherent, and it is possible to run a serious business inside it.

A compliant supplier describes the material rather than its effects: identity, sequence, purity, batch number, analytical method. It publishes batch-specific certificates of analysis — a certificate tied to a batch code that can be matched to the vial in hand, not a generic document reused across the catalogue. It supplies lyophilised material intended for laboratory reconstitution rather than administration-ready formats. It gives no dosing guidance and names no conditions. And its research-only terms match the rest of the site, instead of contradicting everything above them.

Reading a supplier against the test

This gives a straightforward way to assess any vendor in the sector.

If product pages name conditions or symptoms, that supplier has reclassified its own catalogue as unlicensed medicines, whatever the footer says. If the guides section contains human protocols, the same applies. If the certificate of analysis is a single generic PDF with no batch code, then no verifiable analytical claim is being made at all — the document is decoration.

There is a reasonable inference to draw from all of this beyond the legal question. Compliance is one of the cheaper things a supplier can get right: it costs restraint in the copywriting and nothing else. A supplier that will not pay that price, and makes claims about what a compound does to a person in order to convert a sale, has disclosed something about its general standards. Batch testing, cold chain handling and traceability all cost considerably more than restraint does.

The underlying point

Research-only status is a constraint on what a supplier is permitted to say, and the reason the constraint exists is that nobody has done the clinical work that would license these compounds for use in people. The regulations are not an inconvenient technicality sitting on top of a settled science. They are a reasonably accurate reflection of how much is actually known.

Treating the restriction as the honest description of the position, rather than as a loophole to be worked around, is both the lawful approach and the accurate one.

A supplier willing to tell you what a compound will do for you is telling you something useful — just not about the compound.

References

Documented, batch-tested, research use only

Pioneer publishes a batch-specific certificate of analysis for every compound we supply, matched to the batch code on the vial.

View compounds Batch certificates